News >

BiTEs and CAR T Cells Burst Through ALL Paradigm

Ellie Leick
Published: Monday, Mar 09, 2020

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center

Mohammad Maher Abdul-Hay, MD

Bispecific T-cell engagers (BiTEs), specifically blinatumomab (Blincyto), have become a novel treatment approach for patients with acute lymphocytic leukemia (ALL), explained Mohammad Maher Abdul-Hay, MD, adding that CAR T-cell therapy has also transformed treatment for patients ≤25 years old.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication